Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan, Oxaliplatin, and S-1 in Advanced Pancreatic Cancer
NCT03726021Phase 2Completed
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Jan 2018
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan, oxaliplatin and tegafur in pancreatic adenocarcinoma (PDAC), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Primary endpoint: Overall Survival at 2 years. Started Jan 2018; status: completed.
02
Drugs
irinotecanoxaliplatintegafur
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03726021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03726021.